Previous 10 | Next 10 |
home / stock / kaltf / kaltf news
SAN FRANCISCO, July 15, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the " Company " or " Kalytera ") announces that it has received conditional approval from the TSX Venture Exchange ( " TSXV ”) and partial revocation orders from the Briti...
SAN FRANCISCO, June 30, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the " Company " or " Kalytera ") today provided updates regarding the following three matters: (1) the delay in filing of its annual financial statements for the year ending Decem...
SAN FRANCISCO, June 16, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the " Company " or " Kalytera ") announced today that it is working with Salzman Group toward completing definitive agreements for Kalytera’s acquisition of Salzman Group (...
SAN FRANCISCO, June 15, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the " Company " or " Kalytera ") today announced proof-of-concept data demonstrating that R-107 reduces tissue damage and increases survival in a lethal rodent model of chlorine i...
SAN FRANCISCO, June 09, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the " Company " or " Kalytera ") today announced new proof-of-concept data for R-107, its liquid nitric oxide donor, in treatment of pulmonary arterial hypertension ( “PAH&...
Kalytera Therapeutics ( OTC:KALTF +70.3% ) says R-107 readily converts in vivo into its active payload R-100, which accumulates and provides for a sustained release of nitric oxide into lung tissues. More news on: Kalytera Therapeutics Inc., Healthcare stocks news, Read more ...
SAN FRANCISCO, June 05, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the " Company " or " Kalytera ") today announced new in vivo data demonstrating that R-107 exhibits rapid conversion to its active payload R-100 in rats, followed by sustained rel...
SAN FRANCISCO, June 02, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the " Company " or " Kalytera ") today announced that Salzman Group, Inc. has filed a provisional patent application protecting the use of its proprietary, liquid, nitric oxide do...
SAN FRANCISCO, May 29, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the " Company " or " Kalytera ") today announced new proof-of-concept data demonstrating that R-107 reduces tissue damage and preserves organ function in a lethal rodent model of s...
SAN FRANCISCO, May 25, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the " Company " or " Kalytera ") today issued the following letter to shareholders from the Company’s President and CEO, Robert Farrell. Dear Kalytera Shareholders, I...
News, Short Squeeze, Breakout and More Instantly...
Kalytera Therapeutics Company Name:
KALTF Stock Symbol:
OTCMKTS Market:
Kalytera Therapeutics Website:
SAN FRANCISCO, CA and TORONTO, ON , Feb. 22, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") today announced that it has received comments from the Australian Human Research Ethics Committee (the “...
SAN FRANCISCO, CA and TORONTO, ON, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") today announced that the Australian Human Research Ethics Committee (HREC) will meet on February 16 th to...
SAN FRANCISCO, CA and TORONTO, ON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the “ Company ” or “ Claritas ”) today announced revised, improved pricing for the initial tranche of funds that the Co...